Fulgent Genetics (FLGT) logo

Fulgent Genetics (FLGT) stock

Genetic testing , market cap $692M

$24.12
-2.66%

Quality Score
2
Below Average
In its industry
#12of 19
Checks firing
4of 14
Trending up
From 52-week high
-22.3%
under its best in a year

FLGT's Quality Score fell 1 point on Fri, Nov 20, to 2. It did not trade higher than the day before.

See FLGT's 14 chart checksSee FLGT's 14 chart checksSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why FLGT rose on Nov 6

Up 27% on Nov 6, and still 29% over its Nov 5 close.

  • Its Nov 5 results: revenue was $90.4M, up 8%. It rose 27% on Nov 6.

Sources: Price history, Nov 6, 2026; Company release, Nov 5, 2026

1 more reason, free with an account →See every reason on FLGT →3 more reasons why FLGT rose on Nov 6, from its filings, with the timeline and its peers, for Pro members.

Why FLGT still lags the market over five years

Down 74% over the five years to Nov 20 while the S&P 500 rose 58%; up 27% on Nov 6.

3 reasons, from its filings, with the timeline, for Pro members.

Key facts on FLGT

Key facts on FLGT
Since its Dec 2021 highDown 76% profit $507.4M → a $90.9M loss a year
Latest filing8-K, Nov 18 Took on new debt

FLGT in the news

Fri Nov 6Fulgent Genetics Inc (FLGT) Q3 2026 Earnings Call Highlights: Revenue Climbs 8% as Anatomic ... SEC filing 4:08 PM ET · Yahoo Finance and 1 more FLGT closed +27.2% that day.

FLGT catalysts

Coming up

After its last 4 reports it closed -9.0% on average, higher 1 of 4 times.

18 past catalysts since 2020, with sizes and sources, for Pro members.

Why FLGT scores 2

Below Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means

  • +4Chart checks 4 of 14 firing right now, one point each
  • +1Long-term trend above a rising 200-⁠day average, down over one year
  • Run-up adds
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Dilution, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on FLGT and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:50 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when FLGT's Quality Score turns up

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

How FLGT ranks in Diagnostics

FLGT is #12 of 19 by Quality Score.

How FLGT ranks in Diagnostics
RankStockQuality Score
12Fulgent Genetics (FLGT) logoFLGTFulgent Genetics2

More in Diagnostics

When does FLGT report earnings, and what happens after?

Expected to report Fri Feb 26, after the close (in 97 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What FLGT reported on Nov 5, 2026

The quarter

The figures are not read from the release yet.

“We are pleased with our third quarter results, driven by the improvement in our collection rates.”

The filing on EDGAR

Where the sales came from

FLGT's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
MeasureFigure
FY 2026
Non-GAAP EPS$(1.65) $(1.75)raised

Figures as filed (SEC filing, Nov 5)

5 more outlook lines, for Pro members.

In the company's words

  • “We made great progress to address the billing system issue and remain confident in our outlook for the remainder of the year.”

From its results filing (SEC filing · Nov 5)

1 more sentence, for Pro members.

The numbers

Market value
$692M
today
Sales
$330M
up 4.7% on the year
Free cash flow
-$1.4M
last 12 months

Sales fell 5.2% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 5.1% a year over 5 years.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on FLGT: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-7.0%-18.1%+27.2%
May 1Jul 30Nov 5
ReportedGapReaction5
days
Nov 5, 2026After close+9.7%+27.2%+33.2%
Jul 30, 2026After close-14.3%-18.1%-8.2%
May 1, 2026Before open-7.6%-7.0%-0.5%

FLGT closed higher after 1 of its last 4 reports.

All 4 reports, and FLGT's Quality Score going into each

FLGT sales and profit by year

Sales and profit by year

Sales grew in four of the last seven years, to $323M in 2025. It made a profit in three of the eight years.

FLGT has 4 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on FLGT, and all 14 on every stock.Get in free →See the top 3 →Start Pro

FLGT RSI on Nov 20: 56.9, above its 50-day and 200-day averages

Not scored

RSI 56.9, MACD above signal, above both averages. Not scored.

The deep dive on FLGT

  • What it does and how it makes money3 findingsAn operating loss of $91.1M in fiscal 2025, on $323M of sales.Annual report, filed Feb 27, 2026
  • Where it stands4 findingsFor Pro members4 findings on where FLGT stands: its cash, debt, and share count, for Pro members
  • What changed in its filings7 findings"In or around February 2026, the U.S. District Court for the Central District of California unsealed a qui tam complaint (and certain related proceedings) filed against Fulgent Genetics, Inc. and Fulgent Therapeutics LLC by a qui tam plaintiff (known as a relator) on behalf of the United States." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 5, 2026A new heading in its "Risk Factors" this year: "Our tax returns and positions are currently, and may again in the future be, subject to review and audit by the Internal Revenue Service, or the IRS, and other tax authorities …" (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 27, 2026, against the one of Feb 28, 2025"The increase in anatomic pathology services was primarily due to $21.8 million and $41.3 million of revenue in the three and nine months ended September 30 …" (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 5, 2026
  • Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades FLGT, for Pro members

12 more findings on FLGT, each with its source, for Pro members.

FLGT insider trades

2 insiders sold $223K across 8 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellJian Xie$42KPresident and COOat $19.66 on Sep 2, filed Sep 3

All 8 insider filings on FLGT from the last six months, for Pro members.

All FLGT insider trades

FLGT's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold FLGT?

In ETFs: FLGT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Fulgent Genetics

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

1,315 employeesEl Monte, CAfulgentgenetics.com

What Fulgent Genetics says it competes with

“The competitors in our laboratory services business include dozens of companies focused on pathology, genetic, and diagnostic testing services, including specialty and reference laboratories that offer traditional single-gene and multi-gene tests and other diagnostic test providers.”

From its annual report, SEC filing · Feb 27, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on FLGT and every other stock.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn FLGT's score around: 8 things
  • 3 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawaySep 3Jian Xie sold FLGT$42K at $19.66, filed Sep 3

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: FLGT's Quality Score is 2 (Below Average), #12 of 19 in Diagnostics. Insiders sold $223K in the last 6 months (Form 4).

What does FLGT's Quality Score say?

FLGT scores 2 today, which Breakaway calls Below Average. It is #12 of 19 in Services-⁠Medical Laboratories by Quality Score, with 4 of 14 chart checks firing. Up 27% on Nov 6, and still 29% over its Nov 5 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is FLGT's Quality Score?

FLGT scores 2 today, which Breakaway calls Below Average (0 to 5). That is #12 of 19 in Services-⁠Medical Laboratories by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind FLGT's 2.

Are insiders buying FLGT?

2 insiders sold $223K across 8 filings in the last 6 months. No open-⁠market buys on record. The newest is Jian Xie, President and COO, who sold $42K on Sep 2. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.